Enhancing Neurostimulation in Drug-Resistant Epilepsy via Thalamic SEEG

Overview

Thalamic stereoEEG (SEEG) is crucial for optimizing neuromodulation strategies in drug-resistant epilepsy (DRE). Responsive neurostimulation (RNS) targeting thalamic nuclei shows significant seizure reduction and quality-of-life improvements, highlighting the importance of individualized thalamic network mapping.

Background

Epilepsy surgery remains underutilized despite evidence supporting its efficacy in reducing seizures or achieving seizure freedom. Responsive neurostimulation (RNS) offers an alternative for patients not eligible for traditional surgery, with thalamic targets increasingly recognized for their role in seizure propagation. The thalamus, particularly nuclei such as the anterior (ANT), centromedian (CM), and pulvinar, plays a key role in seizure networks. Hypothesis-driven thalamic SEEG enables precise identification of seizure network nodes to guide effective neuromodulation.

Data Highlights

Key Findings

• Less than 1% of eligible DRE patients undergo epilepsy surgery annually despite proven benefits.
• RNS targeting thalamic nuclei achieves median seizure reductions of 58-82% over several years, with a subset achieving seizure freedom.
• Thalamic nuclei ANT, CM, and pulvinar have distinct roles in seizure propagation and are targeted based on individual seizure network hypotheses.
• Hypothesis-driven thalamic SEEG is essential for identifying optimal stimulation sites and improving neuromodulation outcomes.
• ANT-DBS shows variable real-world effectiveness, underscoring the need for individualized network mapping.
• Thalamic neuromodulation reduces sudden unexplained death in epilepsy (SUDEP) by approximately 66%.

Clinical Implications

Clinicians should incorporate hypothesis-driven thalamic SEEG into routine evaluation of patients with drug-resistant epilepsy to tailor neuromodulation strategies effectively. Targeting specific thalamic nuclei based on individual seizure network involvement can enhance seizure control and improve quality of life. Additionally, thalamic neuromodulation offers a promising approach to reduce SUDEP risk.

Conclusion

Thalamic SEEG-guided neuromodulation represents a critical advancement in managing drug-resistant epilepsy, enabling personalized targeting of seizure networks and improving long-term outcomes. Continued accumulation of empirical data will refine these approaches and expand their clinical utility.

References

1. RNS Pivotal Trial -- Long-term seizure reduction with responsive neurostimulation
2. Real-world RNS Study -- Effectiveness of responsive neurostimulation in clinical practice
3. SUDEP Reduction Studies -- Impact of RNS and thalamic DBS on sudden unexplained death in epilepsy
4. Corticothalamic RNS Study -- Seizure outcomes targeting ANT, CM, and pulvinar nuclei
5. Bilateral CM-region RNS Study -- Outcomes in generalized and focal-to-bilateral tonic-clonic epilepsies
6. ANT-DBS SANTÉ Trial -- Efficacy of anterior nucleus thalamic stimulation
7. ANT-DBS MORE Registry -- Real-world effectiveness of ANT-DBS